Bayer’s BlueRock Therapeutics Gains FDA Fast Track for Parkinson’s Disease Cell Therapy

Share This Story, Choose Your Platform!

BlueRock – a Bayer subsidiary – is currently evaluating the pluripotent stem cell-derived dopaminergic neuron therapy in a phase 1 study. This early-stage trial is set to enrol ten patients across the US and Canada, with its primary objective to assess the safety and tolerability of DA01 cell transplantation at one-year post-transplant. Read more…